96 related articles for article (PubMed ID: 24604079)
1. Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models.
Vianello S; Consolaro F; Bich C; Cancela JM; Roulot M; Lanchec E; Touboul D; Brunelle A; Israël M; Benoit E; de la Porte S
FASEB J; 2014 Jun; 28(6):2603-19. PubMed ID: 24604079
[TBL] [Abstract][Full Text] [Related]
2. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
Vianello S; Yu H; Voisin V; Haddad H; He X; Foutz AS; Sebrié C; Gillet B; Roulot M; Fougerousse F; Perronnet C; Vaillend C; Matecki S; Escolar D; Bossi L; Israël M; de la Porte S
FASEB J; 2013 Jun; 27(6):2256-69. PubMed ID: 23430975
[TBL] [Abstract][Full Text] [Related]
3. L-arginine improves dystrophic phenotype in mdx mice.
Voisin V; Sébrié C; Matecki S; Yu H; Gillet B; Ramonatxo M; Israël M; De la Porte S
Neurobiol Dis; 2005 Oct; 20(1):123-30. PubMed ID: 16137573
[TBL] [Abstract][Full Text] [Related]
4. Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy.
Guerron AD; Rawat R; Sali A; Spurney CF; Pistilli E; Cha HJ; Pandey GS; Gernapudi R; Francia D; Farajian V; Escolar DM; Bossi L; Becker M; Zerr P; de la Porte S; Gordish-Dressman H; Partridge T; Hoffman EP; Nagaraju K
PLoS One; 2010 Jun; 5(6):e11220. PubMed ID: 20574530
[TBL] [Abstract][Full Text] [Related]
5. Arginine butyrate per os protects mdx mice against cardiomyopathy, kyphosis and changes in axonal excitability.
Vianello S; Bouyon S; Benoit E; Sebrié C; Boerio D; Herbin M; Roulot M; Fromes Y; de la Porte S
Neurobiol Dis; 2014 Nov; 71():325-33. PubMed ID: 25167832
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of L-arginine benefits mdx skeletal muscle function.
Barton ER; Morris L; Kawana M; Bish LT; Toursel T
Muscle Nerve; 2005 Dec; 32(6):751-60. PubMed ID: 16116642
[TBL] [Abstract][Full Text] [Related]
8. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
[TBL] [Abstract][Full Text] [Related]
9. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice.
Fogagnolo Mauricio A; Minatel E; Santo Neto H; Marques MJ
Clin Nutr; 2013 Aug; 32(4):636-42. PubMed ID: 23218947
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy.
Chaubourt E; Fossier P; Baux G; Leprince C; Israël M; De La Porte S
Neurobiol Dis; 1999 Dec; 6(6):499-507. PubMed ID: 10600405
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice.
Perronnet C; Chagneau C; Le Blanc P; Samson-Desvignes N; Mornet D; Laroche S; De La Porte S; Vaillend C
Hum Mol Genet; 2012 May; 21(10):2263-76. PubMed ID: 22343141
[TBL] [Abstract][Full Text] [Related]
12. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness.
Marques MJ; Ventura Machado R; Minatel E; Santo Neto H
Muscle Nerve; 2008 Jan; 37(1):61-7. PubMed ID: 17724738
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice.
Chakkalakal JV; Harrison MA; Carbonetto S; Chin E; Michel RN; Jasmin BJ
Hum Mol Genet; 2004 Feb; 13(4):379-88. PubMed ID: 14681302
[TBL] [Abstract][Full Text] [Related]
14. Whole body periodic acceleration is an effective therapy to ameliorate muscular dystrophy in mdx mice.
Altamirano F; Perez CF; Liu M; Widrick J; Barton ER; Allen PD; Adams JA; Lopez JR
PLoS One; 2014; 9(9):e106590. PubMed ID: 25181488
[TBL] [Abstract][Full Text] [Related]
15. Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNA-binding protein KSRP and inhibition of AU-rich element-mediated mRNA decay: implications for novel DMD therapeutics.
Amirouche A; Tadesse H; Lunde JA; Bélanger G; Côté J; Jasmin BJ
Hum Mol Genet; 2013 Aug; 22(15):3093-111. PubMed ID: 23575223
[TBL] [Abstract][Full Text] [Related]
16. Functional improvement of dystrophic muscle by myostatin blockade.
Bogdanovich S; Krag TO; Barton ER; Morris LD; Whittemore LA; Ahima RS; Khurana TS
Nature; 2002 Nov; 420(6914):418-21. PubMed ID: 12459784
[TBL] [Abstract][Full Text] [Related]
17. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort.
Archer JD; Vargas CC; Anderson JE
FASEB J; 2006 Apr; 20(6):738-40. PubMed ID: 16464957
[TBL] [Abstract][Full Text] [Related]
18. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
Colussi C; Mozzetta C; Gurtner A; Illi B; Rosati J; Straino S; Ragone G; Pescatori M; Zaccagnini G; Antonini A; Minetti G; Martelli F; Piaggio G; Gallinari P; Steinkuhler C; Clementi E; Dell'Aversana C; Altucci L; Mai A; Capogrossi MC; Puri PL; Gaetano C
Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19183-7. PubMed ID: 19047631
[TBL] [Abstract][Full Text] [Related]
19. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
[TBL] [Abstract][Full Text] [Related]
20. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant.
Burdi R; Didonna MP; Pignol B; Nico B; Mangieri D; Rolland JF; Camerino C; Zallone A; Ferro P; Andreetta F; Confalonieri P; De Luca A
Neuromuscul Disord; 2006 Apr; 16(4):237-48. PubMed ID: 16542837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
